Last reviewed · How we verify
NCT06585189
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
trial testing Pembrolizumab in Metastatic Non Small Cell Lung Cancer in 304 participants. Completed in 13 April 2023.
13 April 2023
Quick facts
| Lead sponsor | Aetion, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 304 |
| Start date | 1 February 2010 |
| Primary completion | 13 April 2023 |
| Estimated completion | 13 April 2023 |
Drugs / interventions tested
- Pembrolizumab (pembrolizumab) — full drug profile →
- Pemetrexed — full drug profile →
- Cisplatin (cisplatin) — full drug profile →
- Carboplatin (Carboplatin) — full drug profile →
Conditions studied
- Metastatic Non Small Cell Lung Cancer — all drugs for Metastatic Non Small Cell Lung Cancer →
Sponsor
Aetion, Inc. — full company profile →
Who can join
18 and older, any sex, with Metastatic Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this non-interventional study is to emulate the KEYNOTE-189 randomized controlled trial of pembrolizumab for the treatment of metastatic non-small cell lung cancer using real-world, electronic health record data. The main questions this study aims to answer are: 1. Do patients with metastatic non-small cell lung cancer (NSCLC) treated with pemetrexed, cisplatin/carboplatin, and pembrolizumab have improved real-world overall survival (rwOS) and real-world progression-free survival (rwPFS) compared with patients treated with pemetrexed and cisplatin/carboplatin alone? 2. How do the results of this non-interventional study compare to those of the KEYNOTE-189 randomized controlled trial?
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06585189
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pembrolizumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
Other recruiting trials for Metastatic Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
- NCT06066138 — A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · Phase 1 · recruiting
- NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc · recruiting
- NCT06863233 — A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer · Phase 1 · recruiting
- NCT06731413 — Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
Other Aetion, Inc. trials
Trials by the same sponsor.
- NCT05908799 — Emulation of the KEYNOTE-189 Trial Using Electronic Health Records · completed
- NCT05638932 — Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments · completed
- NCT04926571 — Dexamethasone and COVID-19 Inpatient Mortality · completed
- NCT06607601 — CARE Initiative: Real-world Emulation of the PALOMA-2 Trial · completed
- NCT06607393 — CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06585189 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aetion, Inc.
- Last refreshed: 5 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06585189.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing